Jeff Yass’s AC Immune ACIU Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$127K Sell
53,369
-35,893
-40% -$98.9K ﹤0.01% 12317
2026
Q1
$245K Sell
89,262
-58,363
-40% -$181K ﹤0.01% 11303
2025
Q4
$464K Buy
147,625
+125,785
+576% +$397K ﹤0.01% 8970
2025
Q3
$63.1K Buy
+21,840
New +$49.3K ﹤0.01% 11779
2023
Q4
Sell
-71,487
Closed -$230K 12250
2023
Q3
$204K Sell
71,487
-3,885
-5% -$11.8K ﹤0.01% 10188
2023
Q2
$223K Buy
75,372
+62,972
+508% +$137K ﹤0.01% 10056
2023
Q1
$29K Sell
12,400
-47,516
-79% -$110K ﹤0.01% 11927
2022
Q4
$122K Buy
+59,916
New +$154K ﹤0.01% 10745
2022
Q3
Sell
-16,546
Closed -$52.1K 13061
2022
Q2
$60K Sell
16,546
-9,562
-37% -$32.7K ﹤0.01% 11863
2022
Q1
$104K Sell
26,108
-56,399
-68% -$244K ﹤0.01% 11872
2021
Q4
$408K Buy
+82,507
New +$480K ﹤0.01% 9715
2021
Q2
Sell
-58,088
Closed -$401K 12470
2021
Q1
$442K Sell
58,088
-74,630
-56% -$533K ﹤0.01% 9758
2020
Q4
$686K Buy
132,718
+80,959
+156% +$413K ﹤0.01% 7593
2020
Q3
$253K Buy
51,759
+40,312
+352% +$289K ﹤0.01% 9039
2020
Q2
$77K Buy
+11,447
New +$83.2K ﹤0.01% 9610

Other funds holding ACIU

Jeff Yass's ACIU Position: Q2 2026 in Review

Jeff Yass reduced its AC Immune (ACIU) stake by 40% in Q2 2026, selling an estimated $98.9K and leaving 53,369 shares worth $127K. The position accounts for ﹤0.01% of the portfolio, ranked #12317.

Jeff Yass first reported a position in ACIU in Q2 2020 and has held it in 15 quarters since. The position peaked at $686K in Q4 2020. 43 funds tracked by Wall St. Rank hold ACIU as of Q2 2026.

  • Jeff Yass held 53,369 shares of AC Immune worth $127K as of Q2 2026.
  • Jeff Yass sold 35,893 AC Immune shares in Q2 2026, an estimated $98.9K.
  • AC Immune made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #12317 holding.
  • Jeff Yass first reported a position in AC Immune in Q2 2020 and has held it in 15 quarters since.
  • Jeff Yass's AC Immune position peaked at $686K in Q4 2020.
  • 43 funds tracked by Wall St. Rank held AC Immune as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.